ライフサイエンスコーパス: adjuvant chemotherapy

1 4 to < 30 v >/= 30 kg/m(2); prior v no prior adjuvant chemotherapy).

2 al survival benefits from fluorouracil-based adjuvant chemotherapy.

3 005, and December 31, 2010, and treated with adjuvant chemotherapy.

4 inant Ang1 variant) improved the efficacy of adjuvant chemotherapy.

5 ion, orbital external-beam radiotherapy, and adjuvant chemotherapy.

6 val after treatment with anthracycline-based adjuvant chemotherapy.

7 tients with stage II CRC who did not receive adjuvant chemotherapy.

8 hological criteria in selecting patients for adjuvant chemotherapy.

9 consent prior to starting the first cycle of adjuvant chemotherapy.

10 adenocarcinomas sampled before and after neo-adjuvant chemotherapy.

11 , 363 received preoperative and 328 received adjuvant chemotherapy.

12 mes is unknown, as is the role of dose-dense adjuvant chemotherapy.

13 fter completion of 4 to 6 months of systemic adjuvant chemotherapy.

14 <.001) had decreased likelihood of receiving adjuvant chemotherapy.

15 e separately the benefit of concomitant plus adjuvant chemotherapy.

16 oncologist areas were less likely to receive adjuvant chemotherapy.

17 the association between race and receipt of adjuvant chemotherapy.

18 e for patients with breast cancer undergoing adjuvant chemotherapy.

19 st cancers to help guide recommendations for adjuvant chemotherapy.

20 ings to reduce physician recommendations for adjuvant chemotherapy.

21 ced against the absolute survival benefit of adjuvant chemotherapy.

22 e OS in patients with resected PAC receiving adjuvant chemotherapy.

23 on and/or surgery was performed, followed by adjuvant chemotherapy.

24 Four patients (33.3%) received adjuvant chemotherapy.

25 significant predictor in patients undergoing adjuvant chemotherapy.

26 1.49-6.81); P=0.003) in patients undergoing adjuvant chemotherapy.

27 31 (67%) completed the entire protocol with adjuvant chemotherapy.

28 rouracil group had grade 3-4 toxicity during adjuvant chemotherapy.

29 clitaxel group had grade 3-4 toxicity during adjuvant chemotherapy.

30 25 (53%) completed the entire protocol with adjuvant chemotherapy.

31 recommended patients undergo cystectomy and adjuvant chemotherapy.

32 is, including 203 patients not receiving any adjuvant chemotherapy.

33 ior adjuvant chemotherapy and 6 had no prior adjuvant chemotherapy.

34 ent involvement and received four courses of adjuvant chemotherapy.

35 cate which high-risk patients should receive adjuvant chemotherapy.

36 who go on surveillance rather than receiving adjuvant chemotherapy.

37 y followed by enucleation, radiotherapy, and adjuvant chemotherapy.

38 onomic status were less likely to be offered adjuvant chemotherapy.

39 tify high-risk patients who can benefit from adjuvant chemotherapy.

40 itive status identifies patients who require adjuvant chemotherapy.

41 f age may anticipate a survival benefit from adjuvant chemotherapy.

42 alysis suggest that the elderly benefit from adjuvant chemotherapy.

43 93) who participated in randomized trials of adjuvant chemotherapy.

44 in 1 week, early surgery, and six courses of adjuvant chemotherapy.

45 of patients in the cohort were treated with adjuvant chemotherapy.

46 with stage III colon carcinomas treated with adjuvant chemotherapy.

47 significant survival benefit associated with adjuvant chemotherapy.

48 nephrectomy, patients were followed without adjuvant chemotherapy.

49 ublication, type and quality of studies, and adjuvant chemotherapy.

50 Gy in 1 week, early surgery and 6 courses of adjuvant chemotherapy.

51 enous resection (VR = 28%), and 70% received adjuvant chemotherapy.

52 may be promising direction for the field of adjuvant chemotherapy.

53 e complete excision, and were due to receive adjuvant chemotherapy.

54 ependent cohorts received fluorouracil-based adjuvant chemotherapy.

55 ve and may be recommended as neoadjuvant and adjuvant chemotherapy.

56 either no trastuzumab or trastuzumab, after adjuvant chemotherapy.

57 ations are required to determine the role of adjuvant chemotherapy.

58 ain survival benefit from fluorouracil-based adjuvant chemotherapy.

59 i-Ang2 antibody) as an add-on to neoadjuvant/adjuvant chemotherapy.

60 more days from surgery to the first dose of adjuvant chemotherapy.

61 eing intensively investigated as primary and adjuvant chemotherapies.

62 (HR 0.65, 0.56-0.76) and concomitant without adjuvant chemotherapy (0.80, 0.70-0.93) but not adjuvant

63 ph node positivity ratio (0%: 4.6; 3.4-6.4), adjuvant chemotherapy (2.4; 2.0-3.0), pathologic T stage

64 After cycle 1 of adjuvant chemotherapy, 596 patient questionnaires were c

65 s are associated with delaying initiation of adjuvant chemotherapy 91 or more days.

66 To determine whether adjuvant chemotherapy (AC) after neoadjuvant chemoradiat

67 re is limited evidence to support the use of adjuvant chemotherapy (AC) after radical nephroureterect

68 endorses evaluating >/=12 lymph nodes (LNs), adjuvant chemotherapy (AC) for stage III patients, and A

69 Effectiveness of adjuvant chemotherapy according to time to initiation af

70 In addition, protective effect conferred by adjuvant chemotherapy (ACT) on GC was observed in patien

71 analysis of KRAS mutation in four trials of adjuvant chemotherapy (ACT) versus observation (OBS) to

72 Information regarding NAC, adjuvant chemotherapy (aCT), breast conserving surgery (

73 its predictive value regarding survival from adjuvant chemotherapy (ACT).

74 with both decreased likelihood of receiving adjuvant chemotherapy (adjusted HR = 0.58; 95% CI: 0.45-

75 Adjuvant chemotherapy administered at different time poi

76 orsed a quality metric concerning the use of adjuvant chemotherapy administration in stage III colon

77 s of metastatic progression and suggest that adjuvant chemotherapy affords a survival benefit by dire

78 Two protocols provided further adjuvant chemotherapy after colorectal resection.

79 Further studies on the specific benefits of adjuvant chemotherapy after concomitant chemoradiotherap

80 d, phase 3 trials comparing observation with adjuvant chemotherapy after preoperative (chemo)radiothe

81 Use of adjuvant chemotherapy after the age of 75 years merits c

82 uvant chemotherapy (0.80, 0.70-0.93) but not adjuvant chemotherapy alone (0.87, 0.68-1.12) or inducti

83 tcomes than those who undergo resection with adjuvant chemotherapy alone or chemotherapy with cranial

84 ional OS advantage beyond that achieved with adjuvant chemotherapy alone.

85 Receipt of adjuvant chemotherapy among both white and black patient

86 o developed metastasis, 4 had received prior adjuvant chemotherapy and 6 had no prior adjuvant chemot

87 Adjuvant chemotherapy and G3 and T4 tumors were exclusio

88 The association between adjuvant chemotherapy and improved survival was consiste

89 S receipt was associated with reduced use of adjuvant chemotherapy and lower health care spending amo

90 he extremities, controversy exists regarding adjuvant chemotherapy and radiation therapy.

91 Patients underwent subsequent surgery with adjuvant chemotherapy and radiation therapy.

92 trogen receptor-positive tumors and received adjuvant chemotherapy and radiotherapy for their primary

93 We studied the time trends in use of adjuvant chemotherapy and survival outcomes among these

94 he association between time to initiation of adjuvant chemotherapy and survival was evaluated using C

95 erall survival between patients who received adjuvant chemotherapy and those who underwent observatio

96 at sufficient risk for recurrence to warrant adjuvant chemotherapy and who remained premenopausal, th

97 k histopathologic features were treated with adjuvant chemotherapy, and no metastases were recorded i

98 entified lymph node ratio, administration of adjuvant chemotherapy, and pathologic T stage as being t

99 e status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases

100 Adoption of adjuvant chemotherapy appears to be associated with sign

101 ision combined with radiotherapy and/or (neo)adjuvant chemotherapy as appropriate, and in the palliat

102 , with black patients less likely to receive adjuvant chemotherapy as compared with white patients (r

103 of concomitant chemotherapy with and without adjuvant chemotherapy as distinct groups.

104 greater than 90 days or who did not receive adjuvant chemotherapy at all compared with that in the T

105 I to III between 1997 and 2011 who received adjuvant chemotherapy at our institution were included.

106 emcitabine to anthracycline and taxane-based adjuvant chemotherapy at this dose and schedule confers

107 of stage II patients that might benefit from adjuvant chemotherapy based on lack of CDX2 expression i

108 to demonstrate the feasibility of customized adjuvant chemotherapy based on timely biomarker analysis

109 Validated predictive markers of adjuvant chemotherapy benefit for stage II or III colon

110 ly-breast cancer who had previously received adjuvant chemotherapy but not trastuzumab were randomly

111 in HER2(+) breast cancer patients receiving adjuvant chemotherapy (but not targeted anti-Her2 therap

112 To investigate receipt of adjuvant chemotherapy by age category (18-49, 50-64, and

113 Abscess/anastomotic leak increased time to adjuvant chemotherapy by more than 5-fold.

114 Neo-adjuvant chemotherapy can rapidly and profoundly affect

115 ge oestrogen receptor-negative breast cancer adjuvant chemotherapy cohort (Nottingham-oestrogen recep

116 025, p(interaction)=0.126) when treated with adjuvant chemotherapy compared with patients undergoing

117 with resected periampullary adenocarcinoma, adjuvant chemotherapy, compared with observation, was no

118 women with breast cancer receiving standard adjuvant chemotherapy conducted at 11 outpatient oncolog

119 to conventional prognostic factors to guide adjuvant chemotherapy (CT) decisions.

120 Group (ISG) had shown a survival benefit of adjuvant chemotherapy (CT) in high-risk extremity soft t

121 mpared overall survival after neoadjuvant or adjuvant chemotherapy (CT), radiotherapy (RT), or combin

122 Optimizing adjuvant chemotherapy decision making based on the 70-ge

123 is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-making.

124 at miR-1269a is a potential marker to inform adjuvant chemotherapy decisions for CRC patients and a p

125 rofiling assays are frequently used to guide adjuvant chemotherapy decisions in hormone receptor-posi

126 For black patients, receipt of adjuvant chemotherapy did not differ across insurance ca

127 INTERPRETATION: Addition of bevacizumab to adjuvant chemotherapy did not improve overall survival f

128 se-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically

129 Overall, adjuvant chemotherapy did not significantly improve dise

130 erine is a promising candidate in anticancer adjuvant chemotherapy, due to its distinct pharmacologic

131 herapies, and early tumor resection and (neo)adjuvant chemotherapy fails to improve a poor prognosis.

132 After surgery, patients received adjuvant chemotherapy followed by the same targeted ther

133 Ang2/Ang1, anti-Tie2) to improve neoadjuvant/adjuvant chemotherapies for TNBC.

134 Given that randomized trials exploring adjuvant chemotherapy for bladder cancer have been under

135 Adjuvant chemotherapy for breast cancer can have adverse

136 patients were randomized to receive standard adjuvant chemotherapy for breast cancer with either plac

137 the CTCAE system is high in women undergoing adjuvant chemotherapy for breast cancer.

138 rapy completion rates in patients undergoing adjuvant chemotherapy for breast cancer.

139 cologists and travel distance and receipt of adjuvant chemotherapy for colon cancer within 90 days of

140 treatment nonadherence during and following adjuvant chemotherapy for colon cancer.

141 recommended to assess benefits and risks of adjuvant chemotherapy for each patient.

142 Adjuvant chemotherapy for early breast cancer has improv

143 sphamide, methotrexate, and fluorouracil) as adjuvant chemotherapy for early breast cancer.

144 added to anthracycline and taxane-containing adjuvant chemotherapy for early breast cancer.

145 Optimal adjuvant chemotherapy for early-stage breast cancer bala

146 ong women undergoing non-anthracycline-based adjuvant chemotherapy for early-stage breast cancer, the

147 le, was developed to estimate the benefit of adjuvant chemotherapy for hormone receptor-positive brea

148 sociated with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor

149 ablished with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor

150 GS: At present, there is no defined role for adjuvant chemotherapy for meningioma of any grade follow

151 For some women, adjuvant chemotherapy for nonmetastatic breast cancer de

152 Uptake of adjuvant chemotherapy for NSCLC increased in patients ag

153 The role of adjuvant chemotherapy for patients with rectal cancer af

154 d population studies, the precise benefit of adjuvant chemotherapy for patients with rectal cancer fo

155 tly support the routine use of postoperative adjuvant chemotherapy for patients with rectal cancer tr

156 Adjuvant chemotherapy for resected early-stage non-small

157 participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) be

158 ignificant proportion of patients undergoing adjuvant chemotherapy for stage III colon cancer may exp

159 al for stages II and III, fluorouracil-based adjuvant chemotherapy for stage III, and surveillance co

160 ve therapeutic potential in conjunction with adjuvant chemotherapy for TNBC.

161 ed (1:1) by minimisation to either immediate adjuvant chemotherapy (four cycles of gemcitabine plus c

162 2 NSCLC who underwent complete resection and adjuvant chemotherapy from 2006 to 2010 were identified

163 A3-positive NSCLC who did or did not receive adjuvant chemotherapy from 443 centres in 34 countries (

164 ishing the more aggressive ER+ BCa requiring adjuvant chemotherapy from the less aggressive cancers b

165 The patient received adjuvant chemotherapy (Gemcitabine) but expired 10 month

166 atient-reported toxicities, this schedule of adjuvant chemotherapy given during and after radiotherap

167 , 351 patients were randomly assigned to the adjuvant chemotherapy group (175 patients) or to the con

168 Those receiving adjuvant chemotherapy had modestly higher doses ( P = .0

169 Although adjuvant chemotherapy has been shown to have a survival

170 Since the 1990s, fluorouracil-based adjuvant chemotherapy has significantly reduced the risk

171 ox modeling demonstrated that treatment with adjuvant chemotherapy (hazard ratio [HR], 0.78; 95% CI,

172 ated an improvement in overall survival with adjuvant chemotherapy (hazard ratio, 0.70; 95% CI, 0.64

173 icant (p=0.01) in favour of concomitant plus adjuvant chemotherapy (HR 0.65, 0.56-0.76) and concomita

174 : 1.67-5.04, P < 0.001) and patients without adjuvant chemotherapy (HR: 2.38, CI: 1.33-4.35, P = 0.00

175 Adjuvant chemotherapy improves outcomes of patients with

176 Adjuvant chemotherapy improves patient survival rates af

177 We aimed to establish whether adjuvant chemotherapy improves the outcome of such patie

178 ve: To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes of early bre

179 Since the introduction of adjuvant chemotherapy in 2004, no substantial progress h

180 dded to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder

181 , gemcitabine has not been added to standard adjuvant chemotherapy in breast cancer for any subgroup.

182 y mortality after surgery and treatment with adjuvant chemotherapy in colon cancer are poorly underst

183 d to evaluate the addition of bevacizumab to adjuvant chemotherapy in early-stage resected NSCLC.

184 that evaluated the benefit of platinum-based adjuvant chemotherapy in non-small-cell lung cancer were

185 ese data lend further support for the use of adjuvant chemotherapy in patients with locally advanced

186 There is uncertainty on the benefit of adjuvant chemotherapy in patients with stage II colorect

187 iveness of cystectomy versus cystectomy plus adjuvant chemotherapy in real-world patients.

188 rative therapy should be offered 6 months of adjuvant chemotherapy in the absence of contraindication

189 rative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgi

190 Uptake of adjuvant chemotherapy in the elderly increased from 3.3%

191 s) who had completed three or more cycles of adjuvant chemotherapy in the previous 6 to 60 months and

192 to consider when making a recommendation for adjuvant chemotherapy, including tumor size, histopathol

193 PAG5 protein expression, anthracycline-based adjuvant chemotherapy increased breast cancer-specific s

194 The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the

195 with stage I disease have a recurrence, and adjuvant chemotherapy is .

196 have pN2 disease have improved outcomes when adjuvant chemotherapy is administered before, rather tha

197 Randomized trials have demonstrated that adjuvant chemotherapy is associated with improved long-t

198 fluorouracil, and oxaliplatin (FOLFOX)-based adjuvant chemotherapy is controversial, possibly owing t

199 More effective systemic adjuvant chemotherapy is necessary to improve the outcom

200 Adjuvant chemotherapy is not recommended for patients wi

201 s, but not for resectable lesions, for which adjuvant chemotherapy is preferred.

202 not statistically associated with receipt of adjuvant chemotherapy (low v high density: OR, 0.98; P=.

203 In 59 patients receiving adjuvant chemotherapy, low CHD5 expression was associate

204 Disparities in receipt of adjuvant chemotherapy may contribute to higher breast ca

205 Cancelled or delayed administration of adjuvant chemotherapy may partly account for these findi

206 However, adjuvant chemotherapy might benefit patients with a tumo

207 s with N2 NSCLC after complete resection and adjuvant chemotherapy, modern PORT seems to confer an ad

208 igned patients who were scheduled to undergo adjuvant chemotherapy (N = 230) to Onco-Move, OnTrack, o

209 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond.

210 Adjuvant chemotherapy offers a survival benefit to a num

211 g pancreatic surgery and are associated with adjuvant chemotherapy omission and treatment delays.

212 The strongest predictors of adjuvant chemotherapy omission were prolonged postoperat

213 Specific complications associated with adjuvant chemotherapy omission were reintubation (OR = 7

214 The effect of adjuvant chemotherapy on survival for resected soft-tiss

215 We investigated the effect of intensive adjuvant chemotherapy on survival in patients after rese

216 ients undergoing primary enucleation with no adjuvant chemotherapy or radiation with follow-up of at

217 Adjuvant chemotherapy or radiotherapy did not appear to

218 CES signature forecasts patient response to adjuvant chemotherapy or radiotherapy.

219 , other nonanthracycline chemotherapy, or no adjuvant chemotherapy or trastuzumab therapy.

220 y of oncologists were less likely to receive adjuvant chemotherapy (OR, 0.85; P=.03).

221 ratio (OR): 4.6], a pN+ status (OR: 3.3), no adjuvant chemotherapy (OR: 3.0), and presence of LM (OR:

222 node dissection ( P = .0464), and receipt of adjuvant chemotherapy ( P = .0161) were significantly as

223 ther pertuzumab or placebo added to standard adjuvant chemotherapy plus 1 year of treatment with tras

224 st cancer, who had completed neoadjuvant and adjuvant chemotherapy plus trastuzumab with no evidence

225 y cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab.

226 s met study inclusion criteria; 23% received adjuvant chemotherapy postcystectomy.

227 ur multidisciplinary tumor board recommended adjuvant chemotherapy, postmastectomy radiation therapy,

228 ur multidisciplinary tumor board recommended adjuvant chemotherapy, postsurgical radiation therapy, a

229 Adjuvant chemotherapy prolongs survival in patients with

230 Completion of all six cycles of planned adjuvant chemotherapy rather than early initiation was a

231 Overall adjuvant chemotherapy receipt was 57.7%: 61.8% among pat

232 Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and

233 ted with a decreased likelihood of receiving adjuvant chemotherapy, regardless of insurance status.

234 meta-analysis to identify the most effective adjuvant chemotherapy regimen.

235 Different adjuvant chemotherapy regimens are available for early-s

236 (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer i

237 Decisions regarding adjuvant chemotherapy regimens should take into account

238 Adherence to reporting adjuvant chemotherapy-related adverse effects using the

239 In the National Cancer Database, adjuvant chemotherapy remained efficacious when started

240 postoperative plasma, we observe evidence of adjuvant chemotherapy resistance and identify patients w

241 Adjuvant chemotherapy should be recommended for patients

242 s who would ordinarily be advised to receive adjuvant chemotherapy should receive ovarian suppression

243 stage II CRC who received fluorouracil-based adjuvant chemotherapy showed a substantial gain in survi

244 For patients receiving adjuvant chemotherapy, solid-predominant adenocarcinoma

245 ancer surgery may still benefit from delayed adjuvant chemotherapy started up to 4 months after surge

246 With the advent of modern adjuvant chemotherapy strategies, postoperative radiothe

247 hen at least half of the population received adjuvant chemotherapy, the cost increased to $30.2 milli

248 stratified according to nodal status, prior adjuvant chemotherapy, the interval from the last dose o

249 ce to quality indicators ranged from 81% for adjuvant chemotherapy to 98% for curative resection; how

250 6 days after the first day of last course of adjuvant chemotherapy to CM maintenance (cyclophosphamid

251 Administering adjuvant chemotherapy to stage II colon cancer patients

252 ve complications explained nearly 20% of the adjuvant chemotherapy treatment gap for patients with st

253 spectively from patients participating in an adjuvant chemotherapy trial (NCCTG N0147).

254 First-generation adjuvant chemotherapy trials reported a 0.27% 8-year cum

255 ears or older following reporting of pivotal adjuvant chemotherapy trials, but it remained below that

256 ncer (BC), the optimal time to initiation of adjuvant chemotherapy (TTC) after definitive surgery is

257 cing adoption of the assay and its impact on adjuvant chemotherapy use in clinical practice remain im

258 The associations between complications and adjuvant chemotherapy use or treatment delay (>/= 70 day

259 The association of complications on adjuvant chemotherapy use was assessed using hierarchica

260 Adjuvant chemotherapy use was nearly identical between g

261 and under scenarios that reflected different adjuvant chemotherapy use.

262 P53/EGFR comutations in randomized trials of adjuvant chemotherapy versus observation.

263 ed by cystectomy, and cystectomy followed by adjuvant chemotherapy was 14% (95% CI, 11% to 17%), 19%

264 persistent opioid use in patients receiving adjuvant chemotherapy was 15% to 21%, compared with 7% t

265 Overall utilization of adjuvant chemotherapy was 63.2% (1497/2368).

266 ents with high-risk retinoblastoma, systemic adjuvant chemotherapy was administered in 83 patients (7

267 Adjuvant chemotherapy was also associated with a signifi

268 In this observational study, adjuvant chemotherapy was associated with improved survi

269 ancer cohort, MN risk after radiation and/or adjuvant chemotherapy was low but higher than previously

270 Utilization of adjuvant chemotherapy was most common among patients who

271 unsatisfactory, and in 2002, the benefit of adjuvant chemotherapy was not established.

272 o tamoxifen alone versus tamoxifen plus OFS; adjuvant chemotherapy was not permitted.

273 Adjuvant chemotherapy was significantly more effective f

274 at sufficient risk for recurrence such that adjuvant chemotherapy was warranted.

275 Adjuvant chemotherapy was well tolerated, with limited t

276 andomized clinical trials using contemporary adjuvant chemotherapy, we confirm that stromal lymphocyt

277 significantly associated with not receiving adjuvant chemotherapy were age, Eastern Cooperative Onco

278 ular invasion, negative surgical margin, and adjuvant chemotherapy were also associated with better c

279 stage II CRC who had clinical follow-up and adjuvant chemotherapy were analyzed.

280 on which to base the decision to administer adjuvant chemotherapy were compared: the 70-gene signatu

281 pling risk-adapted intensive neoadjuvant and adjuvant chemotherapies with surgery and/or radiotherapy

282 ith colorectal cancer who would benefit from adjuvant chemotherapy with 5-fluorouracil and oxaliplati

283 ormed to determine the potential benefits of adjuvant chemotherapy with and without prophylactic cran

284 Adjuvant chemotherapy with doxorubicin and ifosfamide in

285 igh-risk stage II or stage III colon cancer, adjuvant chemotherapy with fluoropyrimidine monotherapy

286 The patient underwent adjuvant chemotherapy with gemcitabine for 6 months and

287 the only potentially curative treatment, and adjuvant chemotherapy with gemcitabine or S-1, an oral f

288 eral involvement and received six courses of adjuvant chemotherapy with intrathecal thiotepa, consoli

289 alysis of individual patient data to compare adjuvant chemotherapy with observation for patients with

290 istant metastases, who underwent surgery and adjuvant chemotherapy with or without postoperative radi

291 Compared with surgery alone, adjuvant chemotherapy with or without radiation was asso

292 represented at the tumor board meeting, and adjuvant chemotherapy with oxaliplatin and capecitabine

293 However, adjuvant chemotherapy with oxaliplatin is controversial

294 are noninferior to primary cytoreduction and adjuvant chemotherapy with respect to overall and progre

295 tients with ovarian cancer who have received adjuvant chemotherapy with taxanes and platinum compound

296 have been no studies evaluating the role of adjuvant chemotherapy, with or without prophylactic cran

297 patients in the study cohort, 75.7% received adjuvant chemotherapy within 90 days of colectomy.

298 crine therapy alone versus those who require adjuvant chemotherapy would be impactful for improving p

299 01) and this was independent of stage, race, adjuvant chemotherapy, year of study, number of particip

300 ry may delay a patient's ability to tolerate adjuvant chemotherapy, yet the urgency of chemotherapy i